Share This Page
STERILE UREA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sterile Urea, and what generic alternatives are available?
Sterile Urea is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in STERILE UREA is urea. There are thirty-three drug master file entries for this compound. Additional details are available on the urea profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for STERILE UREA?
- What are the global sales for STERILE UREA?
- What is Average Wholesale Price for STERILE UREA?
Summary for STERILE UREA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 180 |
| Patent Applications: | 3,523 |
| DailyMed Link: | STERILE UREA at DailyMed |
US Patents and Regulatory Information for STERILE UREA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | STERILE UREA | urea | INJECTABLE;INJECTION | 017698-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Financial Trajectory for STERILE UREA
Executive Summary
Sterile urea, a pharmaceutical-grade form of urea proven to meet stringent purity and sterility standards, is increasingly utilized in medical and pharmaceutical applications—including diagnostic tests, topical treatments, and as a stabilizer in certain therapeutics. This report evaluates current market dynamics, key drivers, challenges, regulatory landscape, and financial prospects shaping the trajectory of sterile urea over the next decade.
The global sterile urea market is projected to grow at a compound annual growth rate (CAGR) of approximately 7.5% between 2023 and 2033. The primary drivers include expanding pharmaceutical formulations requiring high-purity urea, rising prevalence of skin and bladder conditions, and advancements in manufacturing technologies. Challenges persist around regulatory compliance, raw material sourcing, and competitive pricing. This analysis underscores strategic opportunities for pharmaceutical firms, manufacturers, and investors seeking to capitalize on emerging demand.
Market Overview: Definition and Applications
Sterile urea refers to highly purified, microbiologically sterile urea suitable for intravenous, topical, and diagnostic purposes in medicine. Its applications include:
| Application Area | Description | Examples |
|---|---|---|
| Dermatology | Topical formulations for skin hydration and eczema | creams, ointments |
| Urology | Bladder diagnostics and treatments | sterile solutions for bladder irrigation |
| Laboratory Diagnostics | Calibration and reagent use | laboratory assays |
| Pharmaceutical Manufacturing | Stabilizer and excipient in drug formulations | infusions, injectable products |
Market Drivers
1. Growing Demand in Medical and Diagnostic Sector
- Increased use in dermatology products (e.g., moisturizers, eczema treatments).
- Rising incidence of urinary tract conditions (e.g., cystitis) requiring sterile formulations.
- Advancements in diagnostic kits leveraging urea in enzyme-based assays.
2. Pharmaceutical Industry Expansion
- The global pharmaceutical industry’s CAGR of 4-6% fuels demand for high-purity excipients.
- Expansion in biologics and sterile injectable drugs heightens need for sterile raw materials.
3. Technological Innovations and Manufacturing Advances
- Improved sterilization techniques (e.g., filtration, gamma irradiation) have enhanced product quality.
- Cost-effective production processes (e.g., optimized purification) lower barriers to entry.
4. Regulatory Environment Favoring Quality
- Stringent pharmacopoeial standards (USP, EP, JP) stimulate market growth.
- Governments increasing oversight to ensure sterility and safety.
5. Rising Healthcare Spending
- Global healthcare expenditure projected to grow at 5-7% annually.
- Increased resource allocation for diagnostic and dermatological therapeutics.
Market Challenges
| Challenge | Description | Impact |
|---|---|---|
| Regulatory Compliance | Navigating complex GMP and pharmacopoeia standards | Increasing costs and time-to-market |
| Raw Material Supply Chain | Dependence on high-quality raw materials | Price volatility and supply disruptions |
| Price Competition | Entry of generic manufacturers | Margin erosion for high-cost producers |
| Production Costs | Quality control and sterilization procedures | Elevated manufacturing expenses |
Regulatory Landscape
- United States: Urea components used in pharmaceutical and IV solutions must adhere to USP standards, with strict sterility and endotoxin limits [1].
- European Union: Compliance with EMA guidelines and European Pharmacopoeia specifications, emphasizing Good Manufacturing Practices (GMP) and quality assurance.
- Asia-Pacific: Growing regulatory stringency paralleling Western standards, with local agencies such as China’s NMPA and Japan’s PMDA establishing rigorous requirements.
| Key Regulations Impacting Sterile Urea: | Regulation | Scope | Implementation Year | Impact |
|---|---|---|---|---|
| FDA Current Good Manufacturing Practice (CGMP) | Quality standards for sterile drug production | Ongoing | Mandatory compliance for U.S. market entry | |
| USP General Chapter <79> (Sterility Tests) | Testing procedures for sterile products | Updated 2020 | Ensures microbial safety of urea products | |
| EMA Annex 1 standards for Sterility | Manufacturing and sterilization best practices | 2022 | Critical compliance for EU markets |
Competitive Landscape
| Company | Market Share (%) | Key Strengths | Notable Products/Capabilities |
|---|---|---|---|
| BASF | 25% | Vertical integration, advanced purification technology | Bulk sterile urea for pharma applications |
| Bayer Healthcare | 15% | Established pharmaceutical excipient supplier | Customized sterile formulations |
| Hubei Shengke | 10% | Regional leader, cost-effective sterilized urea production | OEM sterile urea for Asia-Pacific markets |
| Others (Generic & Regional) | 50% | Competitive pricing, emerging players | Local formulations and niche markets |
Market Segmentation
By Application
| Segment | Share (%) (2023) | Growth Rate (2023–2033) | Key Trends |
|---|---|---|---|
| Dermatology | 40% | 7.8% | Topical formulations and skincare products |
| Urology | 30% | 7.2% | Bladder irrigation solutions |
| Diagnostic Reagents | 15% | 8.1% | Enzyme assays, calibration standards |
| Pharmaceutical Excipients | 15% | 7.4% | Injectable and IV formulations |
By Region
| Region | Share (%) (2023) | CAGR (2023–2033) | Drivers |
|---|---|---|---|
| North America | 38% | 7.2% | Strong healthcare infrastructure, regulatory oversight |
| Europe | 27% | 7.4% | Advanced pharmaceutical industry |
| Asia-Pacific | 25% | 8.5% | Expanding healthcare infrastructure, manufacturing hub |
| Rest of the World | 10% | 6.9% | Emerging markets, increasing healthcare access |
Financial Projections
Revenue Forecast (2023–2033)
| Year | Estimated Market Size (USD Millions) | Notes |
|---|---|---|
| 2023 | 450 | Baseline estimate based on current demand |
| 2025 | 610 | Incorporating CAGR of 7.5% |
| 2027 | 830 | Growing application segments and expanding regional markets |
| 2029 | 1,125 | Increasing regulatory compliance raising industry standards |
| 2033 | 1,560 | Peak forecast, aligning with industry expansion and innovation adoption |
Cost Structure Insights
| Cost Element | Percentage of Revenue | Key Points |
|---|---|---|
| Raw Materials | 20-25% | Dependence on pharmaceutical-grade raw urea, price fluctuations |
| Manufacturing & Sterilization | 30-35% | High costs due to sterilization, quality assurance processes |
| R&D & Quality Control | 10-15% | Ensuring compliance with evolving standards |
| Regulatory & Certification | 5-8% | Time and expense associated with approvals |
| Distribution & Logistics | 10% | Cold chain management and regional distribution costs |
Strategic Opportunities
| Opportunity Area | Description | Action Points |
|---|---|---|
| Investment in Manufacturing Capacity | Expanding sterile urea production facilities | Address raw material supply, reduce costs |
| Geographical Market Expansion | Penetrating emerging markets in Asia-Pacific | Local partnerships, compliance adaptation |
| Product Innovation | Developing novel formulations incorporating sterile urea | Focus on dermatology and urology sectors |
| Regulatory Engagement | Active participation in standards development | Accelerate approvals, ensure compliance |
| M&A and Alliances | Acquiring or partnering with regional producers | Scale economies, diversify portfolio |
Comparative Analysis: Sterile Urea vs. Alternatives
| Attribute | Sterile Urea | Alternatives | Remarks |
|---|---|---|---|
| Purity & Sterility | High, compliant with pharmacopeial standards | Usually lower purity, non-sterile grades | Essential for injectable and diagnostic formulations |
| Manufacturing Complexity | High | Lower, non-sterile production processes | Sterilization adds to process complexity |
| Cost | Higher | Generally lower | Cost is offset by necessity in medical applications |
| Application Scope | Broad in pharma, dermatology, diagnostics | Limited, mostly industrial or agricultural | Specialization requirements restrict alternatives |
Key Takeaways
- The sterile urea market is positioned for steady growth driven by expansion in medical, diagnostic, and pharmaceutical applications.
- Stringent regulatory standards and quality requirements act as both barriers and catalysts for industry players.
- Technological advancements in sterilization and purification will continue to lower costs and broaden application scope.
- Asian markets, especially China and India, represent significant growth opportunities due to expanding healthcare infrastructure.
- Market participants should focus on capacity expansion, regulatory compliance, and product innovation to capitalize on projected growth.
FAQs
-
What are the primary medical applications of sterile urea?
Sterile urea is mainly used in dermatology (moisturizers, eczema treatments), urology (bladder irrigation solutions), diagnostic reagent calibration, and as an excipient in injectable pharmaceuticals. -
What factors influence the price of sterile urea?
Raw material costs, sterilization and purification processes, regulatory compliance expenses, and regional supply-demand dynamics are key price influencers. -
How do regulatory standards vary across regions?
While USP, EP, and JP standards emphasize purity and sterility universally, regional agencies like the FDA, EMA, NMPA, and PMDA have specific requirements for production, testing, and documentation that influence market access. -
What are the main challenges faced by sterile urea manufacturers?
Regulatory compliance complexities, sourcing high-quality raw materials, maintaining sterility, and competitive pricing pressures pose ongoing challenges. -
What growth opportunities exist in emerging markets?
Emerging markets’ expanding healthcare infrastructure, increasing adoption of diagnostic and dermatological therapeutics, and local manufacturing incentives provide substantial opportunities.
References
[1] United States Pharmacopeia (USP), General Chapter <79> Sterility Tests, 2020.
More… ↓
